HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

WAY-362450

a synthetic farnesoid X receptor (FXR) agonist that promotes cholesterol lowering in models of dyslipidemia; structure in first source

Also Known As:

FXR-450; XL335

Networked: 7 relevant articles (0 outcomes, 4 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azepines: 11
    - WAY-362450: 7
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - WAY-362450: 7

Experts

1.	Harnish, Douglas C: 3 articles (08/2009 - 02/2009)
2.	Wu, Weibin: 2 articles (01/2019 - 01/2014)
3.	Liu, Qiangyuan: 2 articles (08/2009 - 02/2009)
4.	Wang, Juan: 2 articles (08/2009 - 02/2009)
5.	Zhang, Songwen: 2 articles (08/2009 - 02/2009)
6.	Evans, Mark J: 2 articles (06/2009 - 03/2009)
7.	Gardell, Stephen J: 2 articles (06/2009 - 03/2009)
8.	Krueger, Julie A: 2 articles (06/2009 - 03/2009)
9.	Wang, Shuguang: 2 articles (06/2009 - 03/2009)
10.	Bae, Eun Hui: 1 article (10/2019)

Related Diseases

1.	Dyslipidemias (Dyslipidemia) 03/01/2009 - "These studies demonstrate a consistent ability of WAY-362450 to lower both serum TG and cholesterol levels and suggest that synthetic FXR agonists may have clinical utility in the treatment of mixed dyslipidemia."
2.	Alcoholic Liver Diseases (Alcoholic Liver Disease) 01/03/2014 - "We used a specific agonist of FXR WAY-362450 to study the effect of pharmacological activation of FXR in alcoholic liver disease. "
3.	Liver Diseases (Liver Disease) 01/01/2019 - "In this study, we investigated the mechanism of FXR agonist WAY-362450 induced liver enlargement during treating liver diseases. "
4.	Hepatocellular Carcinoma (Hepatoma) 02/06/2009 - "In this study, we report that two synthetic FXR agonists, WAY-362450 and GW4064, suppressed interleukin-6-induced CRP expression in human Hep3B hepatoma cells. "
5.	Fibrosis (Cirrhosis) 08/01/2009 - "The reduction of hepatic fibrosis by WAY-362450 treatment corresponded to a reduction in hepatic gene expression of fibrosis markers. " 08/01/2009 - "In terms of liver histology, while WAY-362450 treatment showed no impact on hepatic triglyceride accumulation, it significantly reduced inflammatory cell infiltration and hepatic fibrosis. " 08/01/2009 - "Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis." 10/01/2019 - "In addition, GW4064 or WAY-362450 (turofexorate isopropyl) treatment protected against unilateral ureteral obstruction-induced renal fibrosis. "

Related Drugs and Biologics

1.	GW 4064
2.	Cholesterol
3.	Triglycerides (Triacylglycerol)
4.	Methionine (L-Methionine)
5.	Choline (Choline Chloride)
6.	Apolipoproteins E (ApoE)